研究者業績

小佐見 光樹

コサミ コウキ  (Koki Kosami)

基本情報

所属
自治医科大学 地域医療学センター 公衆衛生学部門 助教

J-GLOBAL ID
201401058563621806
Researcher ID
AAE-8873-2019
researchmap会員ID
B000238368

研究キーワード

 2

学歴

 1

論文

 60
  • Koki Kosami, Masanari Kuwabara, Akira Okayama, Ryusuke Ae
    Nutrients 2024年12月30日  
  • Mika Shimamura, Kong Weijie, Toshiaki Nonaka, Koki Kosami, Ryusuke Ae, Koji Fujita, Taiki Matsubayashi, Tadashi Tsukamoto, Nobuo Sanjo, Katsuya Satoh
    Biomolecules 2024年12月25日  
  • Masanari Kuwabara, Ryusuke Ae, Koki Kosami, Mehmet Kanbay, Ana Andres-Hernando, Ichiro Hisatome, Miguel A Lanaspa
    Hypertension research : official journal of the Japanese Society of Hypertension 2024年12月3日  
    Uric acid, the final product of purine metabolism, plays a significant role in hypertension Research on uric acid has advanced significantly, particularly regarding its links to hypertension and cardiovascular disease (CVD). Our 2023 review covered the relationship between uric acid, hypertension; and CVD, however, numerous new studies have emerged since then. This paper provides an update, summarizing recent findings over the past two years on hyperuricemia and its association with hypertension, preeclampsia, arteriosclerosis, kidney disease, sleep-disordered breathing, CVD, and so on. Hyperuricemia, often driven by reduced uric acid excretion or increased production, is influenced by genetic factors and lifestyle habits, including high-purine foods, alcohol, and fructose intake. While hyperuricemia has been proposed to contribute to hypertension and CVD through mechanisms like inflammasome activation and oxidative stress, its causal role remains debated. Further clinical and basic science studies on hyperuricemia and purine metabolism are necessary to clarify its impact on CVD and guide therapeutic approaches.
  • Sotaro Takaki, Tohru Kobayashi, Masanari Kuwabara, Naoto Kato, Koki Kosami, Ryusuke Ae
    Archives of disease in childhood 109(12) 1029-1034 2024年11月19日  
    OBJECTIVES: To identify clinical characteristics of patients with non-refractory Kawasaki disease (KD), which were defined as those who successfully responded to the standard initial intravenous immunoglobulin (IVIG) treatment (2 g/kg/day, single infusion) without any secondary or later additional specific treatments, and to investigate the factors associated with the development of coronary artery (CA) complications in patients with non-refractory KD. DESIGN: Retrospective cohort study. SETTING: Hospitals specialising in paediatrics and hospitals with ≥100 beds and a paediatric department throughout Japan. PATIENTS: A total of 122 489 patients who developed KD across Japan during 2011-2018. MAIN OUTCOME MEASURES: CA abnormalities identified after acute illness of KD (defined as CA sequelae). RESULTS: A total of 69 735 patients with non-refractory KD were identified, of which 672 (0.96%) experienced CA sequelae. Among patients with non-refractory KD, the presence of CA abnormalities identified at initial echocardiographic assessment was strongly associated with CA sequelae (adjusted OR (95% CI): 37.8 (31.9 to 44.7)). CA sequelae was also associated with male patients, infants (<12 months old), older patients (≥60 months old) and patients who received delayed initial IVIG treatment (>7 days from KD onset). Subgroup analyses demonstrated that delayed initial IVIG treatment was significantly associated with the development of CA sequelae in both patients with and without CA abnormalities identified at initial echocardiographic assessment. CONCLUSIONS: Approximately 1% of patients with non-refractory KD may develop CA sequelae. Our findings highlight the importance of initial echocardiographic assessment and early initiation of IVIG treatments for patients with KD.
  • Masanari Kuwabara, Ichiro Hisatome, Ryusuke Ae, Koki Kosami, Yuhei Aoki, Ana Andres-Hernando, Mehmet Kanbay, Miguel A. Lanaspa
    Nutrition, Metabolism and Cardiovascular Diseases 103796-103796 2024年11月  

MISC

 38

所属学協会

 8

共同研究・競争的資金等の研究課題

 1